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Kallikrein-related peptidase 4 (KLK4) is one of the 15 mem-
bers of the human KLK family and a trypsin-like, prostate can-
cer-associated serine protease. Signaling initiated by trypsin-
like serine proteases are transduced across the plasma
membrane primarily by members of the protease-activated
receptor (PAR) family of G protein-coupled receptors. Here we
show, using Ca2 flux assays, that KLK4 signals via both PAR-1
and PAR-2 but not via PAR-4. Dose-response analysis over the
enzyme concentration range 0.1–1000 nM indicated that KLK4-
induced Ca2 mobilization via PAR-1 is more potent than via
PAR-2, whereas KLK4 displayed greater efficacy via the latter
PAR.We confirmed the specificity of KLK4 signaling via PAR-2
using in vitro protease cleavage assays and anti-phospho-ERK1/
2/total ERK1/2 Western blot analysis of PAR-2-overexpressing
and small interfering RNA-mediated receptor knockdown cell
lines. Consistently, confocal microscopy analyses indicated that
KLK4 initiates loss of PAR-2 from the cell surface and receptor
internalization. Immunohistochemical analysis indicated the
co-expression of agonist and PAR-2 in primary prostate cancer
and bone metastases, suggesting that KLK4 signaling via this
receptor will have pathological relevance. These data provide
insight into KLK4-mediated cell signaling and suggest that sig-
nals induced by this enzyme via PARsmay be important in pros-
tate cancer.
Kallikrein-related peptidase 4 (KLK4)2 is a trypsin fold serine
protease from the 15-member human KLK family (1–3). Con-
sistentwith its predicted substrate specificity, which is based on
the presence of an aspartate six residues before the catalytic
serine (1), KLK4 cleaves peptide substrates following arginine
or lysine residues (4–6). In addition, several macromolecular
substrates of potential pathophysiological relevance have been
identified from in vitro studies, including another KLK family
member, pro-prostate-specific antigen (also known as KLK3)
and pro-urokinase-type plasminogen activator (4, 7) as well as
fibrinogen (6) and the urokinase-type plasminogen activator
receptor (7).
KLK4 is highly expressed in normal prostate (1, 3, 8) and
recently this protease has been associated with prostate cancer
progression. For example, stable overexpression of KLK4 in
prostate cancer PC-3 cells resulted in an increased ability of
these cells to migrate, accompanied by a transition from an
epithelial morphology to a fibroblastic shape and, consistently,
a significant decrease in E-cadherin protein levels and an
increase in vimentin expression (11). In addition, using an
inducible expression system, it has been demonstrated that
overexpression of KLK4 results in significantly increased col-
ony formation, migration, and proliferation of PC-3 cells and
another prostate cancer cell line, DU145 (12). Furthermore,
KLK4 protein levels are elevated in malignant prostate com-
pared with normal tissue (12, 13), while prostate cancer patient
serum contains antibodies that bind recombinant KLK4 (14).
Most recently, using co-culture systems, it has been shown that
KLK4 is a potential mediator of cellular interactions between
prostate cancer cells and osteoblasts (bone-forming cells) in
bone metastases (15).
Members of the G protein-coupled receptor (GPCR) sub-
family comprising protease-activated receptor (PAR)-1 to
PAR-4, in contrast to other GPCRs, which are activated by
docking of soluble ligands, are irreversibly activated by the
action of proteases (16–19). Indeed, PAR activation is almost
exclusively mediated by trypsin fold serine proteases with sub-
strate specificity for cleavage following arginine or lysine resi-
dues. Cleavage-inducing activation occurs at a unique site
within the amino-terminal exodomain of the receptor, gener-
ating a new amino terminus that serves as a tethered ligand that
binds intramolecularly, causing allosteric changes within the
PAR, followed by receptor coupling to heterotrimeric G pro-
teins and signal transduction (16). Importantly, cleavage down-
streamof the activation site fails tomobilize Ca2 and results in
unresponsiveness to protease agonists (20, 21). Recently, sev-
eral members of the KLK family have been shown to initiate
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trans-plasmamembrane signal transduction via PARs.Oikono-
mopoulou et al. (22) demonstrated that KLK14 activates PAR-2
and PAR-4 but inactivates (or “disarms”) PAR-1. This group
also showed that KLK5 and KLK6 activate PAR-2 (22). In addi-
tion, Angelo et al. (23) have shown that KLK6 is capable of
cleaving a peptide spanning the PAR-2 activation site but not
peptides spanning the activation site of the other PARs. KLK5
and KLK14 signaling via PAR-2 has been demonstrated inde-
pendently in a study that also showed that KLK7 and KLK8 are
not capable of signaling through this receptor (24).
Since the mechanism by which KLK4 mediates its effects on
cells is not known, we have examined the ability of this protease
to initiate cell signaling via members of the PAR family by
examining changes in intracellular calcium ion concentration.
We show that KLK4 initiates Ca2mobilization via PAR-1 and
PAR-2 but not via PAR-4. Focusing on PAR-2, we have also
examined the ability of KLK4 to activate extracellular signal-
regulated kinase 1/2 (ERK1/2), including siRNA knockdown
approaches, to demonstrate that KLK4 signaling is specifically
mediated by this receptor. The potential physiological rele-
vance of KLK4 signaling via PAR-2 was explored by immuno-
histochemical analysis of agonist and receptor expression in
primary prostate cancer and bone metastasis lesions. We have
also examined cellular consequences of KLK4-mediated signal-
ing via PAR-2 in prostate cancer PC-3 cells.
EXPERIMENTAL PROCEDURES
Reagents—PAR-2 activating peptide (AP; SLIGKV), PAR-1
AP (TFLLR), PAR-4 AP (AYPGKF) as the carboxyl amide, a
peptide spanning the PAR-2 serine protease activation site
(ortho-aminobenzoic acid-SKGR2SLIGK(N-(2,4-dintrophe-
nyl)ethylenediamine)-Asp-OH, where the downward arrow
indicates the cleaved peptide bond), and a tripeptide substrate
for kinetic studies (benzyl-FVR-p-nitroanilide) were fromAus-
pep (Parkville, Australia); trypsin was fromWorthington; ther-
molysin was from Calbiochem; 4-methylumbelliferone,
4-methylumbelliferyl p-guanidinobenzoate, and the thermoly-
sin inhibitor phosphoramidon were from Sigma; and EZ-link
NHS-SS-Biotin and ImmunoPure immobilized streptavidin
were from Pierce. Antibodies were purchased from the follow-
ing vendors: phospho-specific monoclonal antibody to ERK1/2
and rabbit anti-ERK1/2 antibody, Cell Signaling (Beverly, MA);
monoclonal anti-PAR-1 (ATAP2), anti-PAR-2 (SAM11), and
anti-GFP antibodies, Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA); rabbit anti-GAPDH antibody, Abcam (Sapphire
Bioscience Pty. Ltd., Redfern, Australia).
Cell Culture—The nontumorigenic and tumorigenic pros-
tate epithelium-derived cell lines (RWPE-1 and RWPE-2,
respectively) and the prostate cancer-derived cell lines LNCaP,
PC-3, and DU145 were from the American Type Culture Col-
lection (Manassas, VA). Lung murine fibroblasts (LMF) from
Par-1 null mice (25) stably expressing human PAR-1, PAR-2 or
PAR-4 (26) were from Johnson & Johnson Pharmaceutical
Research andDevelopment (Spring House, PA). These cells are
designated PAR-1-LMF, PAR-2-LMF, and PAR-4-LMF,
respectively. Cells were grown in Dulbecco’s modified Eagle’s
medium containing 10% fetal calf serum, 100 units/ml penicil-
lin, and 100g/ml streptomycin (Invitrogen) andpropagated in
95% air, 5% CO2 at 37 °C. Cultures of PAR-1-LMF, PAR-2-
LMF, and PAR-4-LMF murine fibroblasts were supplemented
with 200 g/ml hygromycin B (Invitrogen). Insect Spodoptera
frugiperda Sf9 cells were grown in SF9002 serum-free medium
(Invitrogen) containing 100 units/ml penicillin and 100 g/ml
streptomycin at 27 °C.
Expression Constructs and Transfections—An insect cell
KLK4 expression construct was generated by ligating the
human KLK4 open reading frame, including the prepro region
from the previously published pDNA3.1:KLK4 construct (11),
into the pIB/V5-His vector (Invitrogen). This construct gener-
ates the complete KLK4 amino acid sequence followed by V5
(GKPIPNPLLGLDST) andHis6 tags. Insect Sf9 cellswere trans-
fected using Cellfectin (Invitrogen). A mammalian expression
construct encoding PAR-2 with green fluorescent protein
(GFP) at the COOH terminus was generated in the pEGFP-N1
vector (Clontech, Mountain View, CA). A PCR employing Pfu
DNA polymerase (Invitrogen) was used to amplify the PAR-2
coding region. Following amplification and purification, the
PAR-2 PCR product was restriction-digested and then ligated
into pEGFP-N1. Mammalian cells were transiently transfected
using Lipofectamine (Invitrogen). The sequence of both con-
structs was verified.
Generation and Purification of Recombinant KLK4 (rKLK4)—
Following transfection with the KLK4-pIB/V5-His construct,
stable Sf9 cells were selected with 50g/ml Blasticidin (Invivo-
Gen, San Diego, CA). KLK4 was purified from conditioned
media from these cells using Ni2-nitrilotriacetic acid super-
flow resin by following the instructions of the manufacturer
(Qiagen, Doncaster, Australia). Eluted fractions containing
KLK4, identified by analysis of a Coomassie-stained polyacryl-
amide gel, were pooled and then concentrated. Following dial-
ysis against phosphate-buffered saline (PBS; pH 7.4) at 4 °C
overnight, KLK4 was aliquoted and stored at80 °C.
Activation of rKLK4—Recombinant zymogen KLK4 was
incubated with the metalloendopeptidase thermolysin in PBS
at pH 7.4 for 1 h at 37 °C (KLK4/thermolysin ratio 80:1). The
amount of active enzyme producedwas quantified by active site
titration using the pseudosuicide inhibitor 4-methylumbel-
liferyl p-guanidinobenzoate (27). Zymogen KLK4 and thermo-
lysin-treated KLK4 were examined on a Coomassie-stained
polyacrylamide gel, protein bands were excised, and the amino
terminus of the excised treated KLK4was sequenced by Edman
degradation at the Australian Proteome Analysis Facility
(North Ryde, Australia). Thermolysin activity was stopped by
the addition of phosphoramidon (10 M).
Kinetic Measurements of Activated rKLK4—Determination
of kinetic parameters was performed using 40 nM active rKLK4
against the tripeptide substrate benzyl-FVR-p-nitroanilide.
Assays were performed in 50 mM Tris-HCl (pH 7.4), 20 mM
CaCl2, 0.01% (v/v) Tween 20 at 28 °C by following p-nitroani-
lide release photometrically at 405 nm. Experiments to deter-
mine the kinetics of cleavage of a fluorescence-quenched pep-
tide with sequence spanning the PAR-2 serine protease
activation site were performed at 37 °C in 50 mM Tris-HCl (pH
7.4), 20mMCaCl2, 0.01% (v/v) Tween 20 by continuouslymeas-
uring fluorescence at 440 nm following excitation at 330 nm.
Emissions were monitored over 15 min using a Polarstar
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Optima plate reader (BMG Labtech, Melbourne, Australia).
Enzyme activity was determined from a standard curve gener-
ated from the fluorescence obtained following complete cleav-
age by trypsin of knownamounts of peptide using an absorption
coefficient of 104M1 cm1. Toobtain kcat andKm values, initial
velocity data at each substrate concentration were fitted to the
Michaelis-Menten equation by nonlinear regression analysis
using GraphPad Prism 4.0 (GraphPad Software, San Diego,
CA). Experiments were performed in triplicate on three inde-
pendent occasions with results displayed as means S.E.
Measurement of Changes in Intracellular Ca2—Cells grown
to 80% confluence were washed with PBS, detached nonenzy-
matically, resuspended (4  106 cells/ml) in extracellular
medium (121 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl26H2O, 1.8
mM CaCl2, 5.5 mM glucose, 25 mMHEPES (pH 7.4)) containing
0.2% (w/v) bovine serum albumin (Sigma) and then loadedwith
the fluorescence indicator Fura-2 acetoxymethyl ester (1.0 M;
Invitrogen) at room temperature for 60 min. Cells were then
pelleted followed by resuspension in extracellular medium
(without bovine serum albumin) at a concentration of 2 106
cells/ml for fluorescence measurements. The ratio of fluores-
cence at 510 nm after excitation at 340 and 380 nm was moni-
tored using a Polarstar Optima fluorescent plate reader. Single
agonist treatments were KLK4 (300 nM), trypsin (10 nM),
thrombin (10 nM), PAR-1 AP and PAR-2 AP (100 M), and
PAR-4AP (500M). Displayed data are representative of exper-
iments performed in triplicate and repeated on three independ-
ent occasions. Dose-response experiments were performed
over the KLK4 concentration range of 0.1–1000 nM in triplicate
and performed on three independent occasions with results
displayed as means S.E.
Knockdown of PAR-2 Expression—The mammalian siRNA
expression vector pSilencer 3.1-H1 puro (Ambion, Austin, TX)
was used to reduce expression of PAR-2. Candidate PAR-2
siRNA target sequences were designed as previously described
(28) and then aligned against the human genome data base
using the BLAST algorithm to eliminate those with significant
homology to other genes. Three sequences selected were 5-
GATCCAGGAAGAAGCCTTATTGGTTTCAAGAGAACC-
AATAAGGCTTCTTCCTTTTTTTGGAAA-3, 5- GATCC-
AGTAGACTTGGTGTGAAGATTCAAGAGATCTTCACA-
CCAAGTCTACTTTTTTTGGAAA-3, and 5-GATCCGTA-
GTCGTGAATCTTGTTCATTCAAGAGATGAACAAGAT-
TCACGACTATTTTTTGGAAA-3. The sequences were
synthesized (Sigma) and inserted into the pSilencer 3.1-H1
puro vector (Ambion) according to the instructions of the
manufacturer. Fibroblasts from Par-1 null mice stably
expressing PAR-2 (PAR-2-LMF) were transfected with the
PAR-2 pSilencer 3.1-H1 constructs or the supplied pSilencer
3.1-H1 negative control using Lipofectamine. After 48 h, 2
g/ml puromycin was added to the medium to select for stable
transfected cells. PAR-2 expression levels and agonist-induced
induction of ERK phosphorylation were examined by Western
blot analysis.
PAR-1 and PAR-2 mRNA Expression Analysis—Total RNA
was extracted from cells as previously described (29) and cDNA
synthesized using Superscript II (Invitrogen). Reverse tran-
scription-PCRwas performed as previously described (30) with
primers specific for PAR-1 (5-TGTATCCCATGCAGTCCC-
TCTC-3 and 5-CACCTGGATGGTTTGCTCCTT-3),
PAR-2 (5-AGAAGCCTTATTGGTAAGGTT-3 and 5-
AACATCATGACAGGTGGTGAT-3), or -actin (human
5-TGTCACCTTCACCGTTCCA-3 and 5-CAAGATCAT-
TGCTCCTCCTG-3; mouse 5-CGTGGGCCGCCCTAGGC-
ACCA-3 and 5-TTGGCCTTAGGGTTCAGGGGGG-3).
Cell Surface Biotinylation—PC-3 cells were washed three
times with cold PBS, and then plasmamembrane proteins were
biotinylated by incubation with 1.22 mg/ml EZ-link NHS-SS-
Biotin at 4 °C for 1 h with gentle agitation. The cells were then
washed in PBS prior to lysis in a buffer containing 20 mM
HEPES, 150mMNaCl, 1mMEDTA, and 1%TritonX-100. After
centrifugation, bead immobilized streptavidin was added into
the supernatant and incubated for 15 min on ice to capture
biotinylated proteins. The streptavidin beads were pelleted by
centrifugation, and the supernatant was recovered for analysis
of cytoplasmic (nonbiotinylated) proteins. The beadswere then
washed thoroughly, and associated cell surface (biotinylated)
proteins were eluted into Laemmli sample buffer. Cytoplasmic
and cell surface fractions were examined for PAR-2 byWestern
blot analysis.
Western Blot Analysis—Whole cell lysates were collected in a
buffer containing Triton X-100 (1%, v/v), 50 mM Tris-HCl (pH
7.4), NaCl (150 mM), and protease inhibitor mixture (Roche
Applied Science). Fractions containingmembrane proteins and
soluble proteins were isolated as previously described (31). Pro-
tein concentrations were determined by microbicinchoninic
acid assay (Pierce). For ERK1/2 phosphorylation, cells were
grown to 50% confluence and serum-deprived for 24 h before
treatment, and then collection of whole cell lysates was as
above, except the lysis buffer also contained 1 mM sodium
orthovanadate and 50 mM NaF (Sigma). Equal amounts of
lysates (20g) or biotinylated fractions were separated by SDS-
PAGE and transferred to a nitrocellulose membrane that was
blocked with Odyssey blocking buffer (LI-COR, Lincoln, NE)
containing 0.1% (v/v) Tween 20. Membranes were incubated
overnight at 4 °C with an anti-PAR-1 (1:1000), anti-PAR2
(1:1000), anti-GAPDH (1:1000), anti-ERK (1:1,000), or anti-
phospho-ERK (1:2,000) antibody and then washed before incu-
bation with species-appropriate fluorescently conjugated sec-
ondary antibodies for 1 h at room temperature. Membranes
were analyzed using an Odyssey Infrared Imaging System
(LI-COR; Millennium Science, Surrey Hills, Australia) and
where relevant signal intensity determinedusing LI-COR imag-
ing software and exported toMicrosoft Excel for graphical rep-
resentation as mean  S.E. Significance was examined using
Student’s t test with a p value of0.05 considered significant.
FlowCytometry—Cells grown in serum-freemedia overnight
were detached nonenzymatically, washed in PBS, and then
resuspended at 2  l06 cells/ml. Cells were subjected to non-
permeabilizing fixation in 1% formaldehyde on ice for 5 min,
washedwith PBS, and then resuspended in staining buffer (PBS,
pH7.4, 0.2%bovine serumalbumin). Following incubationwith
an anti-PAR-2 antibody (SAM11; 2 g/106 cells) on ice for 60
min, cells were washed and then incubated with fluorescently
tagged anti-mouse secondary antibody. Cell surface PAR-2 was
assessed using an FC500 flow cytometer (Beckman Coulter,
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Gladesville, Australia). In parallel, to assess the levels of total
PAR-2, following fixation, cells were permeabilized by incubation
with 0.01% Triton X-100 in PBS for 5min at room temperature.
Confocal Microscopy—Cells plated on sterile poly-L-lysine
(Sigma)-coated glass coverslips were allowed to adhere over-
night then transfected with either the PAR-2-GFP expression
construct or vector pEGFP-N1. For agonist treatments, cells
were incubated with either KLK4 (100 nM) or PAR-2 AP (100
M) for 10 min at 37 °C before fixation with 4% (v/v) formalde-
hyde. Nuclei were stained by incubating cells for 5 min at room
temperature with 4,6-diamidino-2-phenylindole (1:1500) in
PBS. Coverslips were mounted on slides, and cells were imaged
with a Leica SP5 confocal microscope (Leica Microsystems,
Sydney, Australia). Images were processed using Adobe Photo-
shop CS3 and displayed using CorelDraw. The amount of
PAR-2 on the cell surface was quantified by examining the flu-
orescence of randomly selected untreated and KLK4-treated
cells (n  15) using ImageJ software (National Institutes of
Health, Bethesda,MD), adapting the approach of Scherrer et al.
(32) for quantifyingGPCR cell surface expression. Briefly, three
cellular regions of interest were defined: the whole cell, the
intracellular region, and the nucleus. The signal obtained for
the whole cell and the intracellular region was corrected for
background signal by subtracting nuclear fluorescence. Cell
surface fluorescence was then obtained by subtracting the cor-
rected value for the intracellular region from the corrected
value for the whole cell. These values were then divided by the
number of pixels contained within each region to give fluores-
cence density values for the cell surface (Di surface) and cyto-
plasm (Di cytoplasm). The ratio of Di surface to Di cytoplasm
was determined to normalize data across the counted cell pop-
ulation. Results are displayed graphically as mean  S.E., and
significance was examined using Student’s t test with a p value
of0.05 considered significant.
Immunohistochemical Analysis—Archival formalin-fixed
paraffin-embedded blocks from primary prostate cancers (n
6; Gleason scores 3  4 to 4  5) and prostate cancer bone
metastases (n  2) were obtained from Sullivan Nicolaides
Pathology (Taringa, Australia) and the Royal Prince Alfred
Hospital (Sydney, Australia), respectively, following institu-
tional ethics approval. Immunohistochemistry was performed
as previously described (33). Briefly, serial sections (4m)were
deparaffinized and then rehydrated, and after antigen retrieval
in urea (5% w/v) in 0.1 M Tris buffer (pH 9.5), serial sections
were incubated in H2O2 (3%, v/v) to quench endogenous per-
oxidase. Sections were then blocked in normal goat serum
(10%) and incubated overnight at 4 °C with either an anti-
PAR-2 monoclonal (SAM11; 1:1000 dilution) or an anti-KLK4
rabbit polyclonal (1:250 dilution) antibody. As negative con-
trols, mouse and rabbit immunoglobulins replaced the
SAM11 and anti-KLK4 primary antibodies, respectively. The
EnVision peroxidase polymer detection system (Dako, Bot-
any, Australia) was used with 3,3-diaminobenzidine (Sigma) as
the chromogen. The sections were counterstained with Mayer’s
hematoxylin, visualized by microscopy (Leitz, Laborlux S, Ger-
many), and photographed using a Nikon OXM1200 digital cam-
era. Images were processed using Adobe Photoshop CS3 and dis-
played using CorelDraw.
RESULTS
Examination of KLK4-initiated Changes in Intracellular
Ca2 Ion Concentration via PARs—For these studies, rKLK4
was purified from the conditioned media of Sf9 insect cells sta-
bly transfected with an expression construct containing the
complete human KLK4 coding sequence in frame with V5 and
polyhistidine-encoding sequences. Amino-terminal sequenc-
ing indicated that thermolysin-activated rKLK4 had the pre-
dicted NH2 terminus of mature active KLK4 (31IINED). The
kinetic parameters obtained for thermolysin-activated rKLK4
against the tripeptide substrate benzyl-FVR-p-nitroanilide
(Km 46.9 M, kcat  1.8 s1, and kcat/Km  38.3 s1mM1)
agreed well with the findings of Matsumura et al. (Km  48.3
M, kcat  1.28 s1, and kcat/Km  38.3 s1mM1) using the
same substrate and rKLK4 generated in Drosophila melano-
gaster S2 cells (34).
Signaling via PARs is initiated almost exclusively by arginine/
lysine-specific serine proteases and induces transient changes
in intracellular Ca2 ion concentration (17). PAR activation
leading to calciummobilization requires proteolytic cleavage at
defined activation sites; cleavage downstream of this site fails to
mobilize Ca2 and results in receptor inactivation (18, 20, 21).
Since the ability of the arginine/lysine-specific serine protease
KLK4 to initiate intracellular signaling has not previously been
examined, we studied the ability of this protease to induce
changes in intracellular [Ca2] in PAR-1-LMF, PAR-2-LMF, or
PAR-4-LMF cells (generated from mouse embryonic fibro-
blasts from Par-1 knock-out mice stably expressing either
PAR-1, PAR-2, or PAR-4 (26)). Cells stably expressing PAR-3
are not available, and this receptor in mice does not mediate
transmembrane signaling, leading to the proposal that PAR-3
acts as a co-receptor for signaling via PAR-4 (35). As shown in
Fig. 1, A and B, activated rKLK4 initiated a prompt, transient
Ca2 mobilization in PAR-1- and PAR-2-expressing cells. In
these experiments, the maximum calcium signal initiated by
rKLK4was higher via cells expressing PAR2 than those express-
ing PAR1 (compare the peak heights in Fig. 1, A and B). The
specificity of the response via PAR-1 and PAR-2 was indicated
by the lack of Ca2 flux in cells expressing PAR-4 in response to
activated rKLK4 (Fig. 1C). Positive control agonists for PAR-1
(thrombin and PAR-1 AP), PAR-2 (trypsin and PAR-2 AP), and
PAR-4 (trypsin and PAR-4 AP) each induced changes in Ca2
concentration in the respective PAR-expressing cells (Fig. 1,
D–I) (36–39), confirming that the receptor expressed by each
cell linewas functional. In addition, PAR-1APdid not signal via
PAR-2 or PAR-4, PAR-2 AP did not signal via PAR-1 or PAR-4,
and PAR-4 AP did not signal via PAR-1 or PAR-2 (data not
shown), confirming that Ca2 mobilization in these cells was
mediated only via the respective PAR. In other controls, pro-
rKLK4 andphosphoramidon-inhibited thermolysin did not ini-
tiate PAR signaling, while PAR-4 cells were shown to have
intact PAR following treatment with activated rKLK4 as the
PAR-4 AP, applied 3 min after protease treatment, induced
transient Ca2mobilization (data not shown).
Concentration Dependence of KLK4-initiated Signaling via
PAR-1 and PAR-2—The concentration-effect curves for KLK4-
mediated activation of PAR-1 and PAR-2 Ca2 signaling are
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shown in Fig. 2. PAR-1-LMF and PAR-2-LMF cells were incu-
bated with increasing concentrations of enzyme over the range
0.1 nM to 1 M. As shown in Fig. 2, A and B, increasing concen-
trations of activated rKLK4 stimulated increased Ca2mobili-
zation via both PARs. The maximum response via PAR-1 was
achieved at 300 nM activated rKLK4 with a concentration to
stimulate half-maximal response (EC50) of30 nM. In contrast,
a maximum dose response via PAR-2 was not achieved at the
maximum concentration of rKLK4 currently available to us.
However, using the dose response achieved at 1Mof rKLK4 as
the lower limit for the maximum response, we estimated that
the lowest value for the EC50 via PAR-2 was 300 nM, which
suggests that KLK4 has higher potency (inverse of EC50) for
PAR-1 than PAR-2.
To compare the efficacy of KLK4-initiated Ca2 mobiliza-
tion via PAR-1- and PAR-2-expressing cells, fluorescence val-
ues obtained at each concentration of rKLK4 were divided by
the highest response observed for each of these PARs, which
was via PAR-2 at 1M rKLK4. As shown in Fig. 2C, this analysis
suggests that KLK4 has greater efficacy for initiating Ca2 sig-
naling via PAR-2 than PAR-1.
KLK4 Rapidly Cleaves a Peptide Spanning the PAR-2 Activa-
tion Site—Since concentration-effect curves indicated that
KLK4 initiated Ca2mobilization displayed higher efficacy via
PAR-2 than via PAR-1 (Fig. 2C), KLK4 activation of PAR-2 was
analyzed further. A fluorescence-quenched peptide spanning
the PAR-2 activation site (ortho-aminobenzoic acid-
SKGR2SLIGK-N-(2,4-dintrophenyl)ethylenediamine), which
is activated by low concentrations of trypsin, tryptase, and acro-
sin but not by high concentrations of thrombin (40), was used to
examine the kinetics of direct PAR-2 cleavage by activated
rKLK4 (40 nM). The activated protease was incubated with
varying concentrations of substrate, and fluorescence was
monitored over time with initial velocities fitted to theMichae-
lis-Menten equation to determine kinetic parameters. As
shown in Fig. 3, KLK4 was able to efficiently cleave the PAR-2
peptide with kinetic parameters of Km 8.0, kcat  7.9 s1, and
kcat/Km  1.0 s1 M1, which are similar to the values
observed for KLK6 against a similar PAR-2 peptide (ortho-ami-
nobenzoic acid-SSKGR2SLIGQ-N-2,4-dintrophenyl)ethyl-
enediamine) of Km 5.6 M, kcat 7.9 s1, and kcat/Km 1.4
s1 M1 (23).
KLK4 Initiates Phosphorylation of ERK via PAR-2—The abil-
ity of KLK4 to signal via PAR-2 was further examined by ana-
lyzing ERK1/2 activation, another intracellular pathway down-
stream of PAR activation (17). We performed Western blot
analysis to detect phosphorylated ERK1/2 in PAR-2-LMF cells
stimulated with activated rKLK4 (10 nM) using total ERK1/2 as
a control for relative expression of the kinase. Trypsin and the
PAR-2 AP were used as positive controls for ERK1/2 activation
FIGURE 1. KLK4 initiated changes in intracellular Ca2 ion concentration
via PARs. PAR-1-LMF, PAR-2-LMF, or PAR-4-LMF cells were incubated with
either activated rKLK4 (300 nM), trypsin (10 nM), thrombin (10 nM), PAR-1 AP
andPAR-2AP (100M), or PAR-4AP (500M) as indicated, and fluorescence at
510 nm was measured following alternating excitation at 340 and 380 nm
(Em510(340/380)) using a fluorescent plate reader. The ratio of Em510(340/380) is
proportional to intracellular Ca2 ion concentration. Thearrow indicates time
of treatment. Data are representative of experiments performed in triplicate,
repeated three times.A–C, PAR-1-, PAR-2-, andPAR-4-expressing cells treated
withKLK4.D–F, PAR-1-, PAR-2-, andPAR-4-expressingcells treatedwith serine
protease agonist (D, thrombin; E and F, trypsin).G–I, PAR-1-, PAR-2-, and PAR-
4-expressing cells treated with AP (G, PAR-1 AP; H, PAR-2 AP; I, PAR-4 AP).
FIGURE 2. Concentration dependence of KLK4 signaling via PAR-1 and
PAR-2. PAR-1-LMF and PAR-2-LMF cells were incubatedwith activated rKLK4
(0.1 nM to 1 M), and fluorescence at 510 nm was measured following alter-
nating excitation at 340 and 380 nm (Em510(340/380)) using a fluorescent plate
reader. Intracellular Ca2 ion mobilization is displayed graphically as a per-
centage of the highest recorded response. Experiments were performed in
triplicate and repeated three times with data displayed as mean  S.E.
A, response of PAR-1-LMF cells to KLK4. B, response of PAR-2-LMF cells to
KLK4. C, graphical comparison of responses of PAR-1-LMF and PAR-2-LMF
cells to activated rKLK4. To normalize values obtained via PAR-1 and PAR-2,
fluorescence values obtained at each concentration of rKLK4were divided by
the highest response observed for each of these two PARs, which was via
PAR-2 at 1M rKLK4. Themaximum response initiated via PAR-1 (300 nM) and
PAR-2 (1 M) is indicated by an arrow and arrowhead, respectively.
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via PAR-2. As shown in Fig. 4A, KLK4 induced ERK1/2 phos-
phorylation within 5 min, with reduced levels of activation
apparent at 15 min. PAR-2 AP and trypsin induced ERK1/2
phosphorylation in a similar time-dependent manner (Fig. 4, B
and C, respectively). The dose response of KLK4-initiated sig-
naling via PAR-2was examined by incubating PAR-2-LMF cells
with increasing amounts of enzyme (0.1–300 nM) and examin-
ing changes in ERK1/2 activation. Consistent with Ca2mobi-
lization assays, as shown in Fig. 4D, increasing concentrations
of activated rKLK4 stimulated increased ERK1/2 activation.
We also examined the specificity of KLK4 signaling via
PAR-2 by using siRNA to reduce the expression levels of this
receptor in PAR-2-LMF cells. We generated three PAR-2
siRNAconstructs and stably transfected these intomouse PAR-
2-LMF cells. As shown in Fig. 5A (left) byWestern blot analysis,
it was apparent that construct 2 effectively reduced PAR-2 lev-
els. Densitometric analysis indicated that this construct
reduced PAR-2 levels by up to 80% (mean 60%), whereas
siRNA constructs 1 and 3 failed to consistently reduce PAR-2
expression levels (Fig. 5A, right). The effect of PAR-2 knock-
down on KLK4-initiated intracellular signaling was examined
by assessing levels of activated and total ERK1/2 in lysates from
controls and cells stably transfected with siRNA construct 2.
Densitometric analysis was used to determine a value for phos-
phorylated ERK at each time point relative to untreated cells
and a value for total ERKat each timepoint relative to untreated
cells; the ratio of these values is the -fold increase of ERK acti-
vation over basal levels (41). When treated with KLK4, cells
transfected with construct 2 showed 70% reduction in
ERK1/2 phosphorylation after 5min relative to cells transfected
FIGURE 3. KLK4 cleavage of a fluorescent quenched peptide substrate
spanning the PAR-2 activation site. Activated rKLK4 was incubated with
varying concentrations of the PAR-2 peptide SKGR2SLIGK (the downward
arrow indicates the activation site), and the inverse of initial velocity (deter-
mined using a fluorescent plate reader) was plotted against the inverse of
substrate concentration to determine the displayed kinetic parameters.
Experiments were performed in triplicate on three separate occasions, and
the data are means S.E.
FIGURE 4.KLK4 activation of PAR-2 induces transient phosphorylation of
ERK. PAR-2-LMF cells were incubated with either activated rKLK4 (10 nM) (A),
PAR-2 activating peptide (100 M) (B), or trypsin (10 nM) (C), and cell lysates
collected at the indicated timeswere analyzed byWestern blot analysis using
anti-ERK and anti-phospho-ERK (p-ERK) antibodies. Each agonist experiment
was performed three timeswith similar results.D, concentration dependence
of KLK4 on ERK1/2 activation. Lysates from PAR-2-LMF cells incubated with
activated rKLK4 (0.1–300 nM) were examined by anti-phospho-ERK and anti-
ERKWestern blot analysis. The ratio of activated to total ERK was determined
by densitometry and is displayed graphically. The data are themean S.E. of
three individual experiments.
FIGURE 5.Changes in levels of phospho-ERK (p-ERK) inducedbyKLK4 are
mediated by PAR-2. A, siRNA-mediated knock-down of PAR-2. PAR-2-LMF
cells were stably transfected with one of three PAR-2 siRNA constructs or a
scrambled sequence siRNA control construct (NS, nonspecific siRNA). Cell
lysates were analyzed by Western blot analysis probing with either an anti-
PAR-2 (SAM-11) or anti-GAPDH antibody. The level of PAR-2 expression rela-
tive to GAPDHwas determined by densitometry and is displayed graphically
as themean S.E. of three individual experiments. B, cells stably transfected
with either PAR-2 siRNA construct 2 or the nonspecific siRNA construct were
incubated with activated rKLK4. Lysates were collected at the indicated time
points and analyzed by anti-ERK and anti-phospho-ERK (p-ERK) Western blot
analysis. Each Western blot analysis is representative of three experiments.
The ratio of phospho-ERK to total ERK is also represented graphically as the
mean  S.E. of three individual experiments. C, as for B, except cells were
incubated with PAR-2 AP. *, p 0.05.
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with a nonspecific control (Fig. 5B). A similar reduction in
ERK1/2 phosphorylation after 5 min was also apparent in cells
with reduced PAR-2 levels that had been treated with PAR-2
AP (Fig. 5C). Consistent with results of Ca2 flux assays, these
data indicate that KLK4 initiates intracellular signaling via
PAR-2.
PAR-1 and PAR-2 in Prostate-derived Cell Lines—We exam-
ined PAR-1 and PAR-2 expression in five prostate cell lines
derived from a range of pathologies, by reverse transcription-
PCR and Western blot analysis using PAR-1-LMF and PAR-2-
LMF cells as positive controls for PAR-1 and PAR-2mRNAand
protein. The cell lines were derived from the following sourc-
es: RWPE1, virus-transformed normal epithelium (42);
RWPE2, Ki-ras-transformed RWPE1 cells (42); LNCaP,
lymph node metastasis (43); PC-3, bone metastasis (44); and
DU145, brain metastasis (45). As shown in Fig. 6A, PAR-1 and
PAR-2 mRNA was detected in each of these cell lines, as indi-
cated by the presence of a specific 125- and 583-bp product,
respectively. Similarly, PAR-1 and PAR-2 protein was detected
at high levels in each of the analyzed cell lines (Fig. 6, B and C).
Consistent with a previous report (46), PAR-1 was predomi-
nantly expressed as an65-kDa protein in each cell line, which
reduced to40 kDa upon treatmentwithN-glycosidase F (data
not shown). Higher PAR-1 molecular weight bands present in
lysates from RWPE-1, RWPE-2, PC-3, and D145 cells are
thought to bemultimeric forms of the protein. In each prostate
cell line, PAR-2 was apparent as bands at 55, 65, 85, and
105 kDa. Consistently, PAR-2 bands at65,85, and105
kDa reduced to the55 kDa band on tunicamycin treatment of
breast cancer-derived cell lines, whereas the85 kDa was also
phosphorylated in these cells (47). Interestingly, for PAR-2 only
the 55 kDa band was apparent in PAR-2-LMF cells, potentially
indicating differential post-translational modification (e.g. gly-
cosylation) of PAR-2 as previously proposed (31).
KLK4 Initiated Signaling in a Prostate-derived Cell Line—
PC-3 cells were selected for analysis of KLK4-initiated signaling
in a prostate-derived cell line. For serine protease-mediated
PAR activation to occur, the receptor must be located on the
cell surface (36). PC-3 cell surface expression of PAR-1 has been
previously reported (48).We assessed plasmamembrane local-
ization of PAR-2 in these cells by cell surface biotinylation and
flow cytometry approaches.
In biotinylation experiments, plasma membrane proteins
were isolated by treating intact PC-3 cells with a biotinylating
agent, and biotinylated (cell surface) proteins were purified
using streptavidin-conjugated beads. As shown in Fig. 7A by
Western blot analysis using a PAR-2-specific monoclonal anti-
body, PAR-2 was detected in both the cytoplasm and plasma
membrane fractions. Reprobing this membrane with an anti-
GAPDH antibody indicated that the plasma membrane frac-
tion purified by biotinylation was largely uncontaminated by
intracellular proteins. Consistent data were obtained from our
flow cytometry analyses. In these experiments, cell surface-lo-
calized PAR-2was assessed by examining PC-3 cells, which had
been subjected to nonpermeabilizing fixation. In parallel, total
PAR-2 was determined by examining PC-3 cells permeabilized
with the detergent Triton X-100. As shown in Fig. 7B, the anti-
PAR-2 antibody detected both plasma membrane-localized
PAR-2 (left) and total PAR-2 (right) well above background lev-
els of fluorescence obtained when the cells were stained only
with the secondary antibody.
The ability of KLK4 to initiate signaling in these cells was
assessed by examining transient changes in Ca2 ion mobiliza-
tion. PAR-1 AP and PAR-2 AP were used as positive controls
for signaling via the respective PARs. KLK4 initiated a prompt,
transient Ca2mobilization in these cells as did PAR-1 AP and
PAR-2 AP (Fig. 7C). The dose response of KLK4-initiated Ca2
mobilization was examined by incubating PC-3 cells with
increasing concentrations of enzyme (0.1–1000 nM). As shown
in Fig. 7D, increasing concentrations of KLK4 stimulated
increased Ca2 mobilization consistent with levels observed
from PAR-2-LMF cells (Fig. 2B). These data indicate that
PAR-2 is expressed in a range of prostate cell lines, that PC-3
cells express functional PAR-1 and PAR-2, and that KLK4 ini-
tiates Ca2mobilization in these cells, consistentwith signaling
via PAR-1 and PAR-2.
KLK4 Induces Loss of PAR-2 from the Surface of Prostate Can-
cer-derived PC-3 Cells—It is known that following activation,
PAR-2 is processed by receptor uncoupling from G proteins
and endocytosis followed by ubiquitination-mediated lysoso-
mal degradation (49–52). We employed confocal microscopy
to quantitatively examine internalization of PAR-2 from the cell
FIGURE 6. PAR-1 and PAR-2 in prostate-derived cell lines. A, RT-PCR analy-
sis of PAR-1 and PAR-2 mRNA expression (30 cycles) in PAR-1-LMF, PAR-2-
LMF, PAR-4-LMF, and prostate-derived cell lines. B, Western blot analysis of
PAR-1 protein expression in prostate-derived cell lines and mouse-derived
PAR-1-LMF cells using an anti-PAR-1 antibody (ATAP2). C, Western blot anal-
ysis of PAR-2 protein expression in prostate-derived cell lines and mouse-
derived PAR-2-LMF cells using an anti-PAR-2 antibody (SAM11).
Kallikrein 4 Signaling via Protease-activated Receptors
MAY 2, 2008•VOLUME 283•NUMBER 18 JOURNAL OF BIOLOGICAL CHEMISTRY 12299
 at Queensland Univ of Technology (CAUL) on M
ay 14, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
surface of KLK4-stimulated PC-3 cells. Cells transiently
expressing PAR-2-GFP were used to facilitate localization of
the receptor. As shown in Fig. 8A, in unstimulated PC-3 cells,
PAR-2was detected at the plasmamembrane (arrowheads) and
in cytoplasmic vesicles, including within structures previously
identified as the Golgi apparatus (50, 53). Stimulation of PAR-
2-GFP-expressing cells with activated rKLK4 (100 nM) for 10
min resulted in internalization of PAR-2 from the cell surface
and endocytosis (Fig. 8A, arrow) (54). In controls, PAR-2 AP
treatment also caused PAR-2 internalization and redistribution
throughout PC-3 cells in a manner similar to KLK4 (data not
shown). As described under “Experimental Procedures,” quan-
titative analysis of these data employing a modification of a
previously described approach (32) was used to determine the
amount of PAR-2 on the cell surface before and after KLK4
stimulation. Cellular regions of interest were defined for the
whole cell, the intracellular region, and the nucleus, (marked on
the example unstimulated cell shown in Fig. 8B (top) as red,
yellow, and blue, respectively (middle)). As shown in Fig. 8B
(bottom), graphical representation of the values obtained from
this analysis indicated that PAR-2 cell surface levels decreased
by80% following stimulation with KLK4. These data indicate
that KLK4 induces loss of PAR-2 from the cell surface and
receptor internalization.
KLK4andPAR-2AreCo-expressed in Primary andBoneMet-
astatic Prostate Cancer—Since we demonstrated that the pros-
tate cancer-associated protease KLK4 initiates intracellular sig-
naling via PAR-2, efficiently cleaves a peptide spanning the
PAR-2 activation site, and induces PAR-2 cellular processing,
we next examined the potential pathological relevance of these
observations by performing immunohistochemical analysis of
six primary prostate cancer tissue specimens. The expression
pattern of receptor and agonist in consecutive tissue sections
was examined using a PAR-2-specificmonoclonal antibody and
our previously described anti-KLK4 antibody (55). Represent-
ative images are shown in Fig. 9. PAR-2 and KLK4 had similar
expression patterns, with both expressed by glandular epithelial
cells with little evidence of stromal staining (Fig. 9, panels A and
B and panels D and E, respectively). PAR-2 was detected in
benign glands (BNG) of benign prostatic hyperplasia (BPH),
prostatic intraepithelial neoplasia (PIN), and cancer (Ca).
Expression levels were higher in regions of PIN and Ca than in
BNG regions of BPH (comparing BNG and PIN in Fig. 9A and
BNGandCa in Fig. 9B). A similar staining patternwas apparent
for KLK4. As published previously (13), prostate cancer tissue
samples showed little KLK4 staining in benign glands, with
stronger staining in regions of PIN (comparing BNGand PIN in
Fig. 9D) and Ca (comparing BNG and Ca in Fig. 9E). Negative
controls were free of staining (Fig. 9, D and H).
Bone metastasis is the cause of significant morbidity and
mortality in prostate cancer patients (56). Recently, we have
shown that KLK4 is expressed by both prostate cancer cells and
osteoblasts in the in vivometastatic bone environment and that
osteoblast-like SaOs2 cells induce KLK4 expression in co-cul-
ture systems with prostate cancer-derived LNCaP and PC-3
cells (15). Accordingly, we performed immunohistochemistry
to examine the expression pattern of KLK4 and PAR-2 in con-
secutive sections from prostate cancer bone metastases from
two patients. As shown in Fig. 10, receptor and agonist had
significant overlap in expression in prostate cancer bonemetas-
tasis. In regions of prostate cancer lesions, PAR2 and KLK4
were highly expressed by prostate cancer cells (Fig. 10,A andC,
respectively). In regions containing prostate cancer lesions and
bone, strong staining of osteoblasts lining the bone surface was
also apparent for both PAR2 andKLK4 (arrows in Fig. 10,B and
D, respectively). Negative controls were free of staining (data
not shown).
DISCUSSION
Intracellular signaling, initiated via activation of members of
the protease-activated receptor family of GPCRs, by the action
of trypsin-like serine proteases is important in physiology and
FIGURE 7. PAR-2 in PC-3 cells. A, Western blot analysis of protein fractions
collected fromPC-3 cells partitioned between cytoplasmic and plasmamem-
brane fractions by cell surface biotinylation. Fractions were analyzed for
PAR-2 using antibody SAM11 and for purity using an antibody against a cyto-
plasmic marker (GAPDH). B, flow cytometry analysis for PAR-2, cell surface
(fixed, nonpermeabilized cells; left) and total (fixed, permeabilized cells; right)
PAR-2. Cells were incubated with either an anti-PAR-2 SAM11 antibody fol-
lowed by a fluorescently tagged secondary antibody (black line) or a fluores-
cently tagged secondary antibody only (gray line). C, KLK4 (left), PAR-1 AP
(middle), and PAR-2 AP (right) initiated changes in intracellular Ca2 ion con-
centration in the prostate cancer-derived PC-3 cell line. Cells were incubated
with either KLK4 (300 nM) or activating peptide (100 M) as indicated, and
fluorescence at 510 nmwasmeasured following alternating excitation at 340
and 380 nm (Em510(340/380)) using a fluorescent plate reader. The ratio of
Em510(340/380) is proportional to intracellular Ca
2 ion concentration. Experi-
ments were performed in triplicate and repeated three times. D, concentra-
tion dependence of KLK4-induced changes in intracellular Ca2 ion concen-
tration in prostate-derived PC-3 cells. Cells were incubated with KLK4 (0.1 nM
to1M), and fluorescencewasmeasured asdescribed inD. Experimentswere
performed in triplicate and repeated three times.
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disease (17, 18, 57). The serine protease agonists responsible for
PAR activation in these settings, where many proteolytic
enzymes can be present, are not well defined. Here we have
analyzed the ability of the arginine/lysine-specific (4, 6, 58),
prostate cancer-associated (11–15) serine protease KLK4 to
initiate intracellular signaling via members of the PAR family.
Our data indicate that KLK4 induces Ca2 mobilization via
PAR-1 and PAR-2 but not via PAR-4. This ability to signal via
more than one PAR is known for other serine proteases. These
include thrombin, which signals via PAR-1 and PAR-4 and also
cleaves PAR-3 (16), trypsin, which activates PAR-2 (37, 53) and
PAR-4 (39), activated Factor X, which, in complex with acti-
vated Factor VII and tissue factor, signals via PAR-1 and PAR-2
(59, 60), and KLK14, which activates both PAR-2 and PAR-4
and inactivates PAR-1 (22). Interestingly, our analysis of Ca2
mobilization in response to KLK4 suggests that although sig-
naling via PAR-1 is more potent than via PAR-2, KLK4 dis-
played greater efficacy for signaling via the latter PAR. This
contrasts with trypsin IV, which had similar potency as well as
efficacy for inducing Ca2 mobilization via these PARs in
receptor-overexpressing cells (61). It is possible that the maxi-
mum signaling via PAR-1 observed by us occurred at lower
KLK4 concentration either because
of lower levels of expression of this
receptor or because at higher
enzyme concentration, KLK4
cleaves PAR-1 other than at the acti-
vation site, thereby inactivating or
“disarming” the receptor. Although
these proposals remain to be tested,
the latter has been suggested to
explain the observations that Ca2
mobilization via PAR-2 in response
to KLK6 reached a maximum at a
much lower concentration than
KLK14, and this maximum
response to KLK6 was much lower
than observed for KLK14 (22). It
was proposed that the responses to
KLK6 were due to a receptor acti-
vating ability at lower enzyme con-
centrations via cleavage of PAR-2 at
the consensus activation site and to
a “disarming” ability at higher con-
centration via cleavage downstream
of the activation site. Thus, it is pos-
sible that KLK4 regulates cellular
activity by differential activation of
PAR-1 and PAR-2, at lower enzyme
concentration signaling via both
PARs and as KLK4 concentration
increases via PAR-2 as PAR-1 is dis-
armed. Alternatively, it is possible
that efficacy was lower via PAR-1,
because this receptor is expressed at
levels lower than PAR-2 on the sur-
face of the cells used in this study.
Due to the ability of KLK4 to sig-
nal via PAR-2 over a broader enzyme concentration range, we
analyzed signaling via this receptor-agonist system in greater
detail and also examined the expression of these proteins dur-
ing prostate cancer progression. Our enzymatic studies, using a
fluorescence-quenched peptide indicated that KLK4 efficiently
cleaves a peptide spanning the PAR-2 activation site, suggesting
that intracellular signaling mediated by KLK4 occurs via direct
proteolytic activation of this receptor. The specificity of KLK4
signaling via PAR-2 was assessed by Western blot analysis of
ERK1/2 activation. We observed that KLK4-induced phospho-
rylation of ERK1/2 could be substantially reduced by siRNA-
mediated knock-down of PAR-2 levels. Our confocal micros-
copy analyses indicated that KLK4-induced intracellular
signaling via PAR-2 is accompanied by loss of this GPCR from
the cell surface and receptor internalization.
Our observation of increased PAR-2 expression during pros-
tate cancer progression is consistent with a recent report show-
ing elevated PAR-2 in regions of prostate cancer comparedwith
adjacent normal glandular epithelial cells in 42%of patient sam-
ples (n 40) (62). These workers also showed that PAR-2 levels
increased with increasing Gleason score (62). In addition, our
finding of PAR-2 expression by osteoblasts in prostate cancer
FIGURE 8. KLK4 induces loss of PAR-2 from the surface of prostate cancer PC-3 cells. A, confocal micros-
copy analysis of PC-3 cells transiently transfectedwith a PAR-2-GFP expression construct. Cells, either unstimu-
lated (left panels) or stimulated with KLK4 (100 nM) for 10 min (right panels), were stained with 4,6-diamidino-
2-phenylindole (DAPI) to identify nuclei, fixed, and then imaged on a Leica SP5 confocal microscope. Cell
surface PAR-2 is indicated by arrowheads in an unstimulated cell (left overlay panel). Endocytosed PAR-2 is
indicated by an arrow in a KLK4-stimulated cell (right overlay panel). B, quantification of cell surface PAR-2 was
performed by examining the fluorescence of randomly selected unstimulated and KLK4 stimulated cells (n
15) using ImageJ software. An unstimulated cell is shown in the upper panel. Cellular regions of interest were
defined for this cell (middlepanel), including thewhole cell, the intracellular region, and thenucleus (red, yellow,
and blue, respectively). The signals obtained for the whole cell and the intracellular region were corrected for
background signal by subtracting nuclear fluorescence. Cell surface fluorescence was then obtained by sub-
tracting the correctedvalue for the intracellular region fromthe correctedvalue for thewhole cell. These values
were thendividedby thenumberof pixels containedwithin each region togive fluorescencedensity values for
the cell surface (Di surface) and cytoplasm (Di cytoplasm). The ratio of Di surface to Di cytoplasm was deter-
mined to normalize data across the counted cell population. Results are displayed graphically as mean S.E.
(bottom).
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bone metastases is consistent with studies in mice demonstrat-
ing that murine osteoblasts also express this receptor in vitro
and in vivo (63). The key observation from our immunohisto-
chemical analysis of PAR-2 andKLK4 co-expression in primary
prostate cancer as well as bone metastasis lesions suggests that
KLK4will contribute to PAR-2 activation in these settings. This
is potentially significant, since recent reports have demon-
strated cancer-associated functional consequences of PAR-2
activation in prostate cancer-derived cell lines. For example, in
LNCaP cells, PAR-2 AP induced activation of members of the
Rho GTPase family (62, 64), proteins that are of critical impor-
tance in cytoskeletal reorganization and cancer (65). In addi-
tion, AP mediated activation of PAR-2-induced activity of the
collagenases matrix metalloprotease 2 and 9 by the prostate
cancer cell lines LNCaP, PC-3, and DU145 (66). Further, it has
been suggested that activation of PAR-2 in bone mediates inhi-
bition of osteoclast differentiation and bone lytic activity, and
this effect is probably mediated by osteoblasts (67). This is
potentially significant, since prostate adenocarcinomas have
primarily an osteoblastic phenotype in bone metastasis lesions
(68). Similarly, cancer-associated functional consequences of
KLK4 expression have been noted in prostate cancer-derived
cell lines. For example, KLK4 overexpression induced an
increased ability of PC-3 cells to migrate, accompanied by a
transition from an epithelial morphology to a fibroblastic shape
and, consistently, a significant decrease in E-cadherin protein
levels and an increase in vimentin (11). In addition, inducible
overexpression of KLK4 resulted in significantly increased col-
ony formation, migration, and proliferation of both PC-3 and
DU145 prostate cancer-derived cells (12). Recently, we have
shown that KLK4 levels increased in LNCaP and PC-3 cells
co-cultured with osteoblast-like SaOs2 cells, whereas KLK4-
overexpressing PC-3 cells had increased migration toward
SaOs2 cell conditionedmedia (15). These reports are suggestive
that KLK4 activation of PAR-2 will be important in prostate
cancer progression in both primary and bone lesions.
It is possible that KLK4-initiated signaling via PAR-1will also
be relevant in prostate cancer. Recently, two reports have con-
sistently identified an increase in expression atmRNA and pro-
tein levels of this receptor during prostate cancer progression,
although the expression pattern reported by these groups dif-
fered (62, 69). Kaushal et al. (69) noted predominant expression
in endothelial cells in cancerous regions with cancer cells also
showing PAR-1 expression in some early and advanced stage
specimens. In contrast, using a different antibody, Black et al.
(62) reported PAR-1 expression in cancer cells in 45% of pros-
tate cancer samples and in periglandular stromal cells in 55% of
higher grade cancers. Thus, although the identity of the cell
types expressing PAR-1 in cancerous prostate is contentious,
loss of prostate organ structure during cancer progression will
expose PAR-1 to KLK4. In addition, of relevance, PAR-1
expression has also been reported in human osteoblast-like
cells (70) and mouse osteoblasts (71), and this GPCR mediates
thrombin-induced proliferation of primary rat osteoblasts (72).
The action of KLK4 on PAR-1 and PAR-2 may be particularly
relevant in more advanced primary prostate cancer and bone
metastatic lesions, since the level of Zn2, an efficient inhibitor
of KLK4 proteolytic activity (IC50  16 M (58)) in normal
prostate, is known to drop 10–20-fold in prostatic tissue and
fluid from prostate cancer patients (73, 74).
Of importance to the regulation of PAR-2 activation in nor-
mal and diseased prostate, in addition to KLK4, three other
prostate-expressed serine proteases can initiate intracellular
FIGURE 9. Immunohistochemical analysis of PAR-2 and KLK4 in prostate.
Consecutive sections were stained with either an anti-PAR-2 monoclonal
antibody (A and B), an anti-KLK4 polyclonal antibody (D and E), or control
anti-mouse (C) or anti-rabbit (F) secondary antibodies. BNG regions, PIN, and
Ca are indicated.
FIGURE 10. Immunohistochemical analysis of PAR-2 andKLK4 inprostate
cancer bone metastasis. Consecutive sections were stained with either an
anti-PAR2 or an anti-KLK4 antibody. A, PAR-2 staining in prostate cancer cells
in a prostate cancer bone metastasis lesion. B, PAR-2 staining in a prostate
cancer bone metastasis lesion showing a region of bone. C, KLK4 staining in
prostate cancer cells in a prostate cancer bone metastasis lesion. D, KLK4
staining in a prostate cancer bone metastasis lesion showing a region of
bone. Bone, Ca cells, and osteoblasts lining the bone surface (arrows) are
indicated.
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signaling via PAR-2 in in vitro systems. These include the type II
transmembrane serine proteases (75) TMPRSS2 (76), and
matriptase/MT-SP1 (77) and another KLK serine protease,
KLK14 (24). The ability of four prostatic serine proteases to
signal via PAR-2 indicates that activation of this receptor in
prostate will require both tight regulation of the activating pro-
teases (for example by the presence of activators and inhibitors)
and spatial and temporal expression of receptor and agonist. In
this respect, although protein or mRNA expression has been
reported for TMPRSS2, matriptase/MT-SP1 and KLK14 by
normal and cancerous prostate epithelial cells (13, 78–80), co-
expression of these enzymes with PAR-2 in normal or diseased
prostate, or bone metastases has not yet been addressed.
Another aspect of regulation of PAR-2 signaling in prostate is
the possibility that these serine proteases will most efficiently
activate PAR-2 via a proteolytic cascade reminiscent of the
blood coagulation (81) and wound healing (82) serine protease
cascades.
PAR-1 and PAR-2 constitute a growing number of KLK4
substrates, including pro-prostate-specific antigen (4), fibrino-
gen (6), pro-urokinase-type plasminogen activator (4), and the
urokinase-type plasminogen activator receptor (7) as well as
type I and type IV collagen at lower efficiency (6). In this study,
we observed that PAR-2-mediated activation of ERK1/2 was
initiated at a lower KLK4 concentration than Ca2 mobiliza-
tion (compare Figs. 2B and 4D). Of relevance, ERK1/2 activa-
tion and Ca2 mobilization can both be initiated via disparate
events at the cell surface, includingGPCR and receptor tyrosine
kinase ligand docking (83–85). Thus, it is possible that KLK4 is
able to cleave/activate other cell surface proteins in addition to
PAR-1 and PAR-2 to initiate the differential induction of Ca2
ion flux and ERK1/2 phosphorylation observed by us.
This study has shown for the first time that the receptors
PAR-1 and PAR-2 are activated by the serine protease KLK4
and that PAR-2 and KLK4 are co-expressed during prostate
cancer progression. In addition to a putative role in this disease,
KLK4 is thought to be critical in dental enamel formation (86).
Also, cell culture approaches (9) and immunohistochemical
analysis (10) indicate potential involvement in ovarian cancer.
Thus, KLK4-mediated cell signaling via PARs may be impor-
tant in prostate cancer and other pathophysiological processes.
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